DiaMedica Therapeutics Inc. DMAC
At closeNov 5, 2026, 6:56 AM EST
Pre-market · Nov 5, 6:56 AM ET
- YTD
- +35.30%
- 1 year
- +60.51%
- Market cap
- 580.78M
- EPS (ttm)
- -0.72
- Shares out
- 42.76M
- Forward P/E
- -7.26
- YTD return
- +35.30%
- 1-year return
- +60.51%
- Volume
- 407.08K
- Avg volume
- 191.34K
- Open
- 10.15
- Previous close
- 10.00
- Day's range
- 10.15 – 11.00
- 52-week range
- 5.25 – 11.00
- Beta
- 1.46
- Analysts
- Strong Buy
- Price target
- 7.00 (-35.0%)
- Earnings date
- Aug 7, 2024
2Y +6.40 (+146.45%)
Key statistics
- Enterprise value
- 122.45M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.14M
- Total cash
- 54.05M
- Total debt
- 388.00K
- Return on equity
- -35.18%
- Short % of float
- 0.59%
- 50-day average
- 4.69
- 200-day average
- 3.61
Analyst view
Consensus: strong buy
- Target (low)
- 6.00
- Target (mean)
- 7.00
- Target (high)
- 8.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.1725.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.15 | -0.15 | 0.00 | 0.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.16 | -0.13 | +0.03 | +18.75% |
| Aug 7, 2024 | Jun 1, 2024 | -0.16 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.16 | -0.14 | +0.02 | +12.50% |
| May 8, 2024 | Mar 1, 2024 | -0.16 | — | — | — |
| Mar 19, 2024 | Dec 1, 2023 | -0.14 | -0.14 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 7, 2024 | HC Wainwright & Co. | init | — | Buy |
| Aug 16, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Mar 21, 2024 | Craig-Hallum | main | Buy | Buy |
| Mar 21, 2024 | Oppenheimer | reit | Outperform | Outperform |
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- diamedica.com
News
DiaMedica Therapeutics Enrolls 200th Patient In ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial 
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target 
DiaMedica Therapeutics Q2 EPS $(0.19) Beats $(0.20) Estimate 
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session 
DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal Growth Restriction 
DiaMedica Receives FDA Written Response About The Need For Additional Nonclinical Reproductive Toxicity Data To Support Continued Development Of DM199 For The Treatment Of Preeclampsia - DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic Stroke
Earnings Scheduled For May 6, 2026 - DiaMedica Therapeutics Q1 EPS $(0.19), Inline
- Earnings Scheduled For March 30, 2026
Your note
Sign in to keep a note on DMAC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GIUFFRE RANDALL MICHAEL | Director | Stock Award(Grant) | Jan 1, 2024 | 411,194 |
| KELLEN SCOTT | Chief Financial Officer | Purchase | Jun 22, 2023 | 32,290 |
| KUNTZ RICHARD P | Director | Stock Award(Grant) | Jan 1, 2024 | 14,285 |
| PARSONS JAMES T CPA | Director | Stock Award(Grant) | Jan 1, 2024 | 59,937 |
| PAULS DIETRICH JOHN | Chief Executive Officer | Purchase | Jun 22, 2023 | 68,591 |
| PILNIK RICHARD D | Director | Stock Award(Grant) | Jan 1, 2024 | 278,602 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cooperman, Leon G. | 3.54% | 1,511,739 | 8.13M | Sep 29, 2024 |
| Vanguard Group Inc | 2.45% | 1,049,029 | 5.64M | Sep 29, 2024 |
| First Manhattan Co. LLC | 1.96% | 839,081 | 4.51M | Sep 29, 2024 |
| Paragon Associates & Paragon Associates Ii Joint Venture | 1.13% | 482,614 | 2.59M | Sep 29, 2024 |
| Bleichroeder LP | 0.89% | 382,317 | 2.05M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.72% | 306,958 | 1.65M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.75% | 747,198 | 4.02M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.59% | 253,733 | 1.36M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 149,057 | 801.18K | Oct 30, 2024 |
| Jacob Discovery Fd | 0.27% | 114,730 | 616.67K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.13% | 55,116 | 296.25K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 48,734 | 261.94K | Oct 30, 2024 |